Abstract: Compositions and methods for the treatment of Chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.

Abstract: The invention relates to pharmacology, pharmacokinetics and toxicology, and more specifically to methods of identifying and predicting inter-patient differences in response to drugs in order to achieve superior efficacy and safety in selected patient populations. It further related to the genetic basis of inter-patient variation in response to therapy, including drug therapy, and to methods for determining and exploiting such differences to improve medical outcomes.

Abstract: The instant invention is directed towards compounds, including diamidines, that inhibit Tdp1 and are useful in the treatment and/or prevention of cancer and parasitic disease.

Abstract: A bioreactor chamber assembly including a bioreactor chamber and an outer chamber assembly is provided. In one design, the bioreactor chamber includes an upper grip assembly having a plurality of struts extending downward terminating in upper grips, each strut terminating in an upper grip, and a lower grip assembly containing one or more sample compartments and a lower grip. A sample can be formed in situ via injection into a sleeve contained within the sample compartment, where the sleeve encloses the upper and lower grips and enables a construct to form attached to these grips. In a second design, a split mold is received in the bioreactor chamber, the split mold having a cavity for receiving the upper and lower grips. Tissue explants and engineered constructs can be held within these grips. Medium level in the sample compartment is controlled, and different lengths of samples can be accommodated in the sample compartment.

Abstract: This invention relates to methods and compositions for the attenuation of HIV-1 replication in human cells, and especially in human macrophages. The invention particularly concerns the use of inhibitors of P21 (CDKN1A) expression to attenuate such replication. The invention particularly concerns the use of antisense P21 oligonucleotides, siRNA and/or 2-cyano-3,12-dioxooleana-1,9-dien28-oic (CDDO) to attenuate such replication.